L. Fissette

发表

Hamster neogenin, a host-cell protein contained in a respiratory syncytial virus candidate vaccine, induces antibody responses in rabbits but not in clinical trial participants

M. Picciolato, I. Dieussaert, W. Dewé, 2020, Human vaccines & immunotherapeutics.

A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant

J. Langley, S. Halperin, Laurence Fissette, 2016, The Journal of infectious diseases.

Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial.

I. Carletti, P. van Damme, P. Kremsner, 2016, Clinical immunology.

Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.

M. Ison, J. Langley, L. Cámpora, 2023, The New England journal of medicine.

Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials

P. van Damme, Laurence Fissette, M. Picciolato, 2018, The Journal of infectious diseases.

Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans

R. A. van den Berg, A. Callegaro, A. Marchant, 2017, Front. Immunol..

Immunogenicity and Safety of a Booster Dose of an Investigational Adjuvanted Polyprotein HIV-1 Vaccine in Healthy Adults and Effect of Administration of Chloroquine

G. Leroux-Roels, M. Janssens, Laurence Fissette, 2014, Clinical and Vaccine Immunology.

Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans.

A. Callegaro, C. Legrand, A. Marchant, 2019, Vaccine.

Impact of adjuvants on CD 4 + T cell and B cell responses to a protein antigen vaccine : Results from a phase II , randomized , multicenter trial

I. Carletti, P. Kremsner, A. Marchant, 2016 .

First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector–Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults

P. Klenerman, A. Leach, P. Cicconi, 2019, Clinical Infectious Diseases.

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial

E. Kerwin, J. Tica, F. Struyf, 2022, The Journal of infectious diseases.

Immunogenicity and Safety of a Booster Dose of the 10-valent Pneumococcal Haemophilus Influenzae Protein D Conjugate Vaccine Coadministered With the Tetravalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine in Toddlers: A Randomized Trial

Tzou-Yien Lin, G. Ruiz-Palacios, Li-Min Huang, 2013, The Pediatric infectious disease journal.

The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial

K. Schmader, M. Levin, D. Curran, 2018, The journals of gerontology. Series A, Biological sciences and medical sciences.

119. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Well Tolerated

E. Kerwin, J. Tica, N. Dezutter, 2020, Open Forum Infectious Diseases.

LB745. Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults ≥ 60 Years of Age (YOA)

M. Ison, J. Langley, F. Martinón-Torres, 2022, Open Forum Infectious Diseases.